<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toxoplasmosis: Ocular disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toxoplasmosis: Ocular disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Toxoplasmosis: Ocular disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Justus G Garweg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eskild Petersen, MD, DMSc, DTM&amp;H</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marlene L Durand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 14, 2020.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Toxoplasmosis, an infection with a worldwide distribution, is caused by the intracellular protozoan parasite, <em>Toxoplasma gondii</em>. Immunocompetent persons with primary infection are usually asymptomatic. However, in some immunocompetent individuals, <em>T. gondii</em> infection can present as an acute systemic infection. Toxoplasmosis can also present as ocular disease (eg, posterior uveitis), presenting either in the context of recently acquired infection or reactivated disease. In some patients, posterior uveitis may be the only symptom of an acute <em>T. gondii</em> infection.</p><p>This topic will review the pathogenesis, clinical manifestations, diagnosis, and treatment of ocular toxoplasmosis. Discussions of acute systemic infection, as well as toxoplasmosis in special populations (individuals with HIV infection, pregnant women, neonates), are presented elsewhere. (See  <a class="medical medical_review" href="/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a> and  <a class="medical medical_review" href="/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a> and  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis"</a>.) </p><p class="headingAnchor" id="H508961808"><span class="h1">IMPORTANCE OF GENOTYPES</span><span class="headingEndMark"> — </span>It is well established that <em>T. gondii</em> can be divided into different genotypes, which are prevalent in different geographic areas. The different genotypes differ in pathogenicity and can therefore impact the clinical presentation and clinical course of <em>T. gondii</em> infection [<a href="#rid1">1</a>]. </p><p>The three main <em>T. gondii</em> genotypes are types I, II, and III. In Europe and the United States, where genotype II is prevalent, 80 to 90 percent of individuals who become infected are asymptomatic. This is in contrast to South and Central America, where genotype I and atypical strains predominate, resulting in a substantially increased severity of clinical disease. As an example, <em>T. gondii</em> infection in South and Central America is associated with much higher rates of posterior uveitis compared with other geographic areas. In Brazil, the seroprevalence of <em>T. gondii</em> has been reported to be as high as 80 percent; the prevalence of ocular toxoplasmosis ranges from 6 to almost 18 percent in immunocompetent individuals with <em>T. gondii</em> infection (depending upon the geographic area) and is seen in approximately 80 percent of children with congenital infection [<a href="#rid2">2-10</a>]. By contrast, ocular toxoplasmosis occurs in less than 2 percent of individuals infected with <em>T. gondii</em> in the United States [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H1381826887"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H642083642"><span class="h2">Scarring without evidence of active disease</span><span class="headingEndMark"> — </span>Most patients with ocular disease due to toxoplasmosis in Europe and North America are asymptomatic. Such patients typically have scarring noted on routine examination without any history or evidence of active retinochoroiditis (<a class="graphic graphic_picture graphicRef121876" href="/d/graphic/121876.html" rel="external">picture 1</a>). (See <a class="local">'Inactive disease'</a> below.)</p><p class="headingAnchor" id="H2177766929"><span class="h2">Posterior uveitis</span><span class="headingEndMark"> — </span>Patients with active ocular disease typically present with posterior uveitis. <em>T. gondii</em> is the most common pathogen to cause posterior uveitis in immunocompetent hosts. (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p>In patients with posterior uveitis, the retina and choroid are the primary sites of inflammation, although secondary vitreal inflammation is typically the symptomatic finding that leads to consultation with an ophthalmologist. </p><p class="headingAnchor" id="H1276065411"><span class="h3">Signs and symptoms</span><span class="headingEndMark"> — </span>Posterior uveitis due to <em>T. gondii</em> typically begins within the retina and spreads into the choroid. Satellites may frequently be found in the area of an active lesion within the neuroretina, which is typical for ocular toxoplasmosis and helpful when differentiating toxoplasmosis from other causes of posterior uveitis. (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a> and <a class="local">'Differential diagnosis'</a> below.)</p><p>Immunocompetent adults with ocular toxoplasmosis typically present with floaters and visual loss, which may be permanent if the lesion affects the macula. Floaters alone are often the presenting sign if the retinochoroidal lesion is not located within the central retina. </p><p>The severity of vitreous inflammation correlates with the parasite strain, parasite load, and the host immune response. Consequently, immunocompetent individuals with acquired disease typically develop more severe vitreal infiltration, whereas elderly and immunocompromised patients develop larger lesions with a less severe vitreal infiltration. These lesions are frequently atypical in their presentation, which leads to a higher risk of early misdiagnosis. (See <a class="local">'Exam findings'</a> below.)</p><p class="headingAnchor" id="H2954197097"><span class="h3">Acute versus reactivated disease</span><span class="headingEndMark"> — </span>Ocular toxoplasmosis can present either in the context of recently acquired infection or reactivated disease.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute ocular disease </strong>– Acute ocular disease can be seen in all age groups. In some patients, posterior uveitis may be the only symptom of acute <em>T. gondii</em> infection. (See  <a class="medical medical_review" href="/d/html/120887.html" rel="external">"Toxoplasmosis: Acute systemic disease"</a>.)</p><p></p><p class="bulletIndent1">It is estimated that up to 2 percent of <em>Toxoplasma</em>-infected people in the United States develop retinochoroiditis associated with primary infection; however, in some patients, ocular findings may not be recognized in the acute phase but detected later as a retinal scar [<a href="#rid12">12</a>]. The risk of developing ocular disease is greater in patients from South and Central America. (See <a class="local">'Importance of genotypes'</a> above.)</p><p></p><p class="bulletIndent1">In children with congenital toxoplasmosis, retinochoroiditis is the most common late manifestation, and patients can develop complications such as visual impairment, retinal detachment, choroidal neovascularization, and optic nerve head involvement [<a href="#rid13">13</a>]. A more detailed discussion of congenital toxoplasmosis is found elsewhere. (See  <a class="medical medical_review" href="/d/html/14426.html" rel="external">"Congenital toxoplasmosis: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactivated disease </strong>– Patients with reactivated ocular disease (presence of old scars and an active lesion) typically have acquired their infection either in utero or postnatally. Immunocompetent patients with reactivation of their disease can present with bilateral involvement, unlike those with recent infection, who typically present with unilateral ocular disease [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent1">Patients can present with reactivated disease at any age. Those who present with ocular toxoplasmosis when they are older than 40 years of age are at higher risk of recurrence than younger patients, and a relapsing and remitting course can develop after a prolonged disease-free interval [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1">In immunocompetent hosts, reactivation of toxoplasmosis almost always presents as retinochoroiditis. This is in contrast to immunocompromised hosts, who often present with central nervous system manifestations. (See  <a class="medical medical_review" href="/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a>.)</p><p></p><p class="headingAnchor" id="H3545231090"><span class="h2">Other manifestations</span><span class="headingEndMark"> — </span>Isolated anterior uveitis has rarely been observed, whereas an anterior segment involvement with granulomatous corneal precipitates and a rise in intraocular pressure may be seen. Optic nerve head involvement and lesions close to the optic disc (Jensen disease) may be clinically less prominent, but result in substantial visual field defects. Similar to posterior uveitis, these manifestations can present during primary or reactivated disease.</p><p class="headingAnchor" id="H28183755"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3123024291"><span class="h2">Inactive disease</span><span class="headingEndMark"> — </span>In typical cases of inactive ocular toxoplasmosis, the diagnosis is based upon characteristic clinical findings in combination with anti-<em>Toxoplasma</em> immunoglobulin G (IgG) antibodies. (See  <a class="medical medical_review" href="/d/html/14003.html" rel="external">"Diagnostic testing for toxoplasmosis infection", section on 'Serologic testing'</a>.) </p><p>The most frequent clinical finding is an inactive scar. Discrete neuroretinal satellites may also be seen, the presence of which supports the diagnosis. (See <a class="local">'Scarring without evidence of active disease'</a> above.) </p><p>If disease activity is absent, laboratory evaluation other than serologic testing to confirm past infection (if requested) is not needed. This is in contrast to active disease, in which combined analysis of blood and ocular fluid (aqueous humor) may be required to confirm the diagnosis. (See <a class="local">'Serologic testing'</a> below and <a class="local">'Aqueous humor analysis'</a> below.)</p><p class="headingAnchor" id="H2146003830"><span class="h2">Active disease</span></p><p class="headingAnchor" id="H3582312098"><span class="h3">When to suspect toxoplasmosis</span><span class="headingEndMark"> — </span>Ocular toxoplasmosis should be suspected in a patient who presents with visual loss or vitreal floaters along with an inflammatory retinal or chorioretinal lesion. The diagnosis of ocular disease is typically suggested by findings on ophthalmologic examination and supported by serologic testing and/or aqueous humor analysis, as described below.</p><p class="headingAnchor" id="H706154847"><span class="h3">Exam findings</span><span class="headingEndMark"> — </span>Findings on ophthalmologic examination usually include mild iritis and marked vitreous inflammation (white blood cells in the vitreous), accompanied by whitish retinal lesions representing retinochoroiditis (<a class="graphic graphic_picture graphicRef121877" href="/d/graphic/121877.html" rel="external">picture 2</a>). However, retinochoroiditis may be masked by the dense vitreous inflammation.</p><p><a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">Fluorescein</a> angiography may be helpful for diagnosis in some cases with optic nerve head involvement or prominent vasculitis (<a class="graphic graphic_picture graphicRef121878" href="/d/graphic/121878.html" rel="external">picture 3</a>), as well as for detection of a presumed secondary choroidal neovascularization. </p><p class="headingAnchor" id="H2725785948"><span class="h3">Serologic testing</span><span class="headingEndMark"> — </span>Testing for IgM and IgG antibodies using an enzyme-linked immunosorbent assay (ELISA) should be performed to support the diagnosis of ocular toxoplasmosis. In acute systemic infection,<em> Toxoplasma</em>-specific IgM antibodies usually appear within 7 to 10 days and can persist for a variable duration. <em>Toxoplasma</em>-specific IgG antibodies develop within approximately two weeks of primary infection, peak within approximately eight weeks, and generally persist for life. (See  <a class="medical medical_review" href="/d/html/14003.html" rel="external">"Diagnostic testing for toxoplasmosis infection", section on 'Serologic testing'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute infection</strong> – In patients who present with ocular disease in the setting of acute infection, IgG is almost always present. IgM may also be present; however, a negative IgM does not exclude the diagnosis, since ocular manifestations usually develop several months after the initial infection and IgM may no longer be present at that time. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactivated disease</strong> – In patients with ocular lesions due to reactivation of a previous infection, IgM antibodies are usually not present, and IgG may range from detectable to increased. However, in immunocompromised patients, serology can be more difficult to interpret. Although a negative <em>Toxoplasma</em>-specific IgG makes the diagnosis of reactivated disease unlikely, rare cases of seronegative ocular disease have been reported, as illustrated in a patient with chronic lymphocytic leukemia who had polymerase chain reaction (PCR)-confirmed ocular toxoplasmosis despite repeatedly negative <em>Toxoplasma</em> IgG [<a href="#rid16">16</a>]. </p><p></p><p>Although a positive IgG antibody test supports the diagnosis of ocular toxoplasmosis, it does not confirm the diagnosis, since IgG alone cannot distinguish active from past infection and posterior uveitis due to other causes can be seen in patients with a previo<em>us T. gondii</em> infection. Thus, if the clinical exam findings are unclear, additional testing may be needed to establish the diagnosis. These tests include antibody testing of paired serum and aqueous humor samples to test for local antibody production, PCR testing of aqueous humor f<em>or T. gondii</em> DNA, and, rarely, cytopathology from vitreal specimen. (See <a class="local">'Aqueous humor analysis'</a> below.)</p><p class="headingAnchor" id="H2179232292"><span class="h3">Aqueous humor analysis</span><span class="headingEndMark"> — </span>In patients with an atypical presentation and in those with disease involving the macula, aqueous humor analysis may be reasonable in conjunction with serum antibody testing. Aqueous humor analysis should include both multiplex and quantitative PCR, as well as antibody testing. Testing should be performed by laboratories with specific experience in the work-up of small volumes of aqueous humor and serum in parallel. The sensitivity and specificity of intraocular antibody detection have been reported to be 63 and 89 percent, respectively [<a href="#rid17">17,18</a>]. The sensitivity of PCR positivity ranges from 15 to 65 percent and depends in part upon the quality of ocular sampling [<a href="#rid19">19,20</a>].</p><p>Once testing is obtained, some laboratories calculate the Goldmann-Witmer coefficient, which can be used as a tool to compare the local versus systemic Toxoplasma-specific IgG. This index compares the relative proportion of Toxoplasma-specific IgG to total IgG in the aqueous humor and in the serum. A value of 2 or above is considered evidence of the intraocular synthesis of Toxoplasma-specific IgG in response to ongoing active disease. </p><p>The use of aqueous humor analysis was supported in a study that included 18 patients with suspected ocular toxoplasmosis, in which ocular toxoplasmosis was confirmed in 15 (83 percent) patients when serum antibody testing was combined with aqueous humor analysis (PCR and antibody testing determining the <em>T. gondii</em>-specific IgG ration between blood and aqueous humor) [<a href="#rid17">17</a>]. In another study that evaluated the use of aqueous humor analysis in 137 immunocompetent patients with posterior uveitis resulting from a suspected infectious etiology, 37 patients had positive results, and of those, 75 percent had evidence of <em>Toxoplasma</em> infection [<a href="#rid21">21</a>]. Most immunocompetent cases were diagnosed using measurements of intraocular antibody production. (See  <a class="medical medical_review" href="/d/html/14003.html" rel="external">"Diagnostic testing for toxoplasmosis infection", section on 'Serologic testing'</a>.) </p><p class="headingAnchor" id="H3522184300"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis depends on the clinical picture and includes all diseases that can present as chorioretinitis or retinal necrosis. (See  <a class="medical medical_review" href="/d/html/8232.html" rel="external">"Retinal vasculitis associated with systemic disorders and infections"</a>.)</p><p>This includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis (see  <a class="medical medical_review" href="/d/html/7999.html" rel="external">"Tuberculosis and the eye"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis (see  <a class="medical medical_review" href="/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis", section on 'Ocular'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lyme disease (see  <a class="medical medical_review" href="/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults", section on 'Ocular manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Syphilis (see  <a class="medical medical_review" href="/d/html/7584.html" rel="external">"Syphilis: Epidemiology, pathophysiology, and clinical manifestations in patients without HIV", section on 'Neurologic findings'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viral retinal necrosis (see  <a class="medical medical_review" href="/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster", section on 'Acute retinal necrosis'</a> and  <a class="medical medical_review" href="/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Ocular manifestations'</a> and  <a class="medical medical_review" href="/d/html/8289.html" rel="external">"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Ocular manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fungal chorioretinitis or endophthalmitis (see  <a class="medical medical_review" href="/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune retinal disease (Behçet, lupus) (see  <a class="medical medical_review" href="/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome", section on 'Ocular disease'</a> and  <a class="medical medical_review" href="/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Ophthalmologic involvement'</a>)</p><p></p><p>If diagnostic testing is not revealing, the diagnosis is sometimes made based upon the clinical response to treatment. (See <a class="local">'Follow-up'</a> below.)</p><p class="headingAnchor" id="H350751924"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>This section will focus on treatment of ocular toxoplasmosis in nonpregnant adults. Patients should be managed by an ophthalmologist experienced in the diagnosis and treatment of retinochoroiditis and uveitis. Special considerations in the management of pregnant women and children are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a> and  <a class="medical medical_review" href="/d/html/15835.html" rel="external">"Congenital toxoplasmosis: Treatment, outcome, and prevention"</a>.) </p><p class="headingAnchor" id="H3813264231"><span class="h2">Antimicrobial therapy for ocular disease</span><span class="headingEndMark"> — </span>Ocular toxoplasmosis is generally treated with oral therapy (eg, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> [TMP-SMX] or <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a>). The duration of therapy is typically six weeks but may be extended based upon the specific regimen and the clinical response. (See <a class="local">'Treatment regimens'</a> below and <a class="local">'Follow-up'</a> below and <a class="local">'Duration of treatment'</a> below.) </p><p>For certain patients (eg, those with severe vitreal infiltration, optic nerve head involvement, or retinal vasculitis), there may be a role for glucocorticoids in combination with antimicrobial therapy [<a href="#rid22">22</a>]. (See <a class="local">'Adjunctive glucocorticoids'</a> below.)</p><p class="headingAnchor" id="H178034982"><span class="h3">Indications</span><span class="headingEndMark"> — </span>The decision to treat ocular toxoplasmosis is typically based upon the clinical presentation (eg, the severity of vision loss, the size and proximity of the lesion to the central retina, the host immune status). </p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with inactive ocular toxoplasmosis, even if newly detected, do not require treatment or regular follow-up as long as they are asymptomatic. However, there are special considerations in children with congenital toxoplasmosis, which are presented in a separate topic review. (See  <a class="medical medical_review" href="/d/html/15835.html" rel="external">"Congenital toxoplasmosis: Treatment, outcome, and prevention", section on 'Whom to treat'</a>.) </p><p></p><p class="bulletIndent1">In addition, some adults with scars who require immunosuppressive therapy may not warrant treatment but would benefit from prophylactic therapy to prevent recurrence. This should be determined on a case-by-case basis. Additional information on the use of prophylactic therapy is found below. (See <a class="local">'Duration of treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with active ocular toxoplasmosis, we suggest antimicrobial therapy for those with ocular findings or conditions that put them at risk for developing site-threatening disease [<a href="#rid23">23-25</a>]. This includes: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lesions threatening the optic nerve or fovea (eg, a central lesion within the vessel arcades or close to the optic disc).</p><p class="bulletIndent2"><span class="glyph">•</span>Decreased visual acuity with or without suspected optic nerve involvement.</p><p class="bulletIndent2"><span class="glyph">•</span>Lesions associated with moderate to severe vitreous inflammation or retinal vasculitis.</p><p class="bulletIndent2"><span class="glyph">•</span>Atypical lesions and lesions greater than one disc diameter in size.</p><p class="bulletIndent2"><span class="glyph">•</span>A progressive or prolonged clinical course (persistence of disease for more than one month).</p><p class="bulletIndent2"><span class="glyph">•</span>The presence of multiple active lesions.</p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompromised patients (eg, patients with HIV/AIDS; those receiving cancer chemotherapy, high-dose systemic corticosteroids, and/or other immunomodulatory therapy).</p><p></p><p class="bulletIndent1">Treatment is also indicated for pregnant women with acquired disease. In such patients, the goal of treatment is also to prevent adverse outcomes in the fetus. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy", section on 'Approach to maternal treatment for reduction of congenital toxoplasmosis'</a>.)</p><p></p><p>Although most cases of active ocular toxoplasmosis resolve spontaneously over the course of four to eight weeks, limited data suggest that systemic antimicrobial therapy (with or without glucocorticoids) may be associated with a reduction of the lesion size in active retinochoroiditis and faster visual recovery [<a href="#rid26">26-31</a>]. As an example, in a prospective multicenter study of 149 patients with ocular toxoplasmosis, patients with central lesions were treated with one of three different antimicrobial regimens in combination with glucocorticoids, whereas those with peripheral lesions did not receive systemic therapy [<a href="#rid27">27</a>]. Approximately half of the 35 patients treated with a pyrimethamine-containing regimen had a reduction in the size of the retinal inflammatory lesion compared with 20 percent (8 of 41) who did not receive systemic therapy. </p><p>The use of antimicrobial therapy may also be associated with a reduced risk of recurrent disease [<a href="#rid29">29,32,33</a>]. In a meta-analysis that included data from three randomized trials with a total of 227 patients, antimicrobial therapy reduced the risk of recurrent retinochoroiditis compared with placebo by approximately 75 percent (risk ratio 0.26, 95% CI 0.11-0.63) [<a href="#rid29">29</a>]. However, the absolute risk varied with the geographic setting; in countries where the risk of ocular disease was low (eg, the United States and Europe), the risk of recurrence decreased from 110 to 26 cases per 1000; by contrast, in areas where the risk of ocular disease was high (eg, Brazil), the risk of recurrence decreased from 250 to 65 cases per 1000.</p><p>Indications for the use of adjunctive glucocorticoids are discussed below. (See <a class="local">'Adjunctive glucocorticoids'</a> below.)</p><p class="headingAnchor" id="H3530276265"><span class="h3">Treatment regimens</span><span class="headingEndMark"> — </span>Ocular toxoplasmosis is generally treated with oral therapy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimens</strong> <strong>in nonpregnant adults</strong> – For nonpregnant adults who require treatment for ocular toxoplasmosis, we administer TMP-SMX (160 mg TMP/800 mg SMX twice daily in patients with normal renal function). Treatment should be administered for a minimum of six weeks. (See <a class="local">'Duration of treatment'</a> below.)</p><p></p><p class="bulletIndent1">Another reasonable option is <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a> plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (pyrimethamine [100 mg] plus sulfadiazine [3 g] given as a single loading dose on the first day of treatment; followed by pyrimethamine [25 mg daily] plus sulfadiazine [1 g three times daily] plus leucovorin [10 mg daily]). </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">Pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a> has traditionally been considered the treatment of choice for ocular toxoplasmosis since there is the most experience with this combination. However, experts are increasingly using TMP-SMX, as limited evidence suggests these regimens have comparable efficacy and there appear to be fewer side effects with TMP-SMX [<a href="#rid34">34,35</a>]. In addition, in some countries pyrimethamine can be expensive and difficult to obtain. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative regimens</strong> <strong>in nonpregnant adults</strong> – If a patient is intolerant to first-line regimens (eg, patients with a sulfonamide allergy), <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> (750 mg four times a day) in combination with <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> (100 mg loading dose followed by 25 mg daily) plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (10 mg per day) for a minimum of six weeks can be used. Atovaquone can be given alone if pyrimethamine is not tolerated or not available; however, in this setting it is given for at least three months [<a href="#rid36">36</a>]. (See <a class="local">'Duration of treatment'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 500 mg daily, ideally in combination with <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> (100 mg loading dose followed by 25 mg daily) plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (10 mg per day), is another option. This regimen appears to be effective, but resolution of findings is slower than with the pyrimethamine-sulfadiazine combination [<a href="#rid37">37</a>]. Treatment should be administered for a minimum of six weeks. (See <a class="local">'Duration of treatment'</a> below.)</p><p></p><p class="bulletIndent1">Intravitreal <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> (1.0 mg/0.1 mL) with one or more injections administered over a period of six weeks can also be used. The number of injections is based upon disease activity on examination. We typically reserve this regimen for those who are intolerant to systemic treatment or as adjunctive treatment to systemic therapy if the lesion approaches the macula. This regimen may be associated with an increased risk of ocular complications (eg, retinal toxicity due to dosing or dilution errors, endophthalmitis) compared with systemic treatment, and it must be applied by a retina specialist [<a href="#rid38">38-40</a>]. In addition, toxoplasmosis is a systemic disease, and intravitreal therapy provides no benefit outside of the eye. Oral clindamycin is not routinely recommended to treat ocular infection because it does not readily pass the blood-ocular barrier and may thus not achieve sufficient intraocular drug concentrations.</p><p></p><p>If <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> (folinic acid) is included as a component of the regimen, it should <strong>not</strong> be replaced by <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a>. Folic acid counteracts the effect of <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> and can result in prolonged disease activity due to incomplete control of parasite proliferation.</p><p>Special considerations regarding antimicrobial therapy for pregnant women and children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a> and  <a class="medical medical_review" href="/d/html/15835.html" rel="external">"Congenital toxoplasmosis: Treatment, outcome, and prevention"</a>.)</p><p class="headingAnchor" id="H178034881"><span class="h2">Adjunctive glucocorticoids</span><span class="headingEndMark"> — </span>We suggest glucocorticoids<strong> </strong>be<strong> </strong>given to<strong> </strong>patients with significant vitreous inflammation and retinal vasculitis in addition to antimicrobial therapy. We believe glucocorticoids<strong> </strong>help preserve vision and enhance visual recovery in this setting; however, there are no definitive data to support the efficacy of glucocorticoids or the best dosing regimen [<a href="#rid41">41</a>]. </p><p></p><p>Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids should be initiated two to three days <strong>after</strong> antimicrobial therapy has been started. Glucocorticoid therapy is usually delayed to reduce parasite proliferation and thereby minimize the likelihood that glucocorticoids will exacerbate the infection. This approach has successfully been used in clinical trials evaluating different treatment regimens for ocular disease [<a href="#rid34">34,42</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial dose of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> is 40 mg, or approximately 0.5 mg/kg of body weight, once per day. After one week, the daily dose can be tapered depending upon the clearing of inflammatory changes. The dose is generally tapered over a few weeks, but it should be &lt;10 mg per day once the systemic antibiotic regimen is stopped. </p><p></p><p>In select settings, if an intravitreal injection of <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a> is used, intravitreal-injected <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> (0.4 mg/0.1 mL) may be added rather than oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> as an adjunctive glucocorticoid. However, the use of this approach must be determined on a case-by-case basis. </p><p>Systemic and, more importantly, intravitreal glucocorticoids must <strong>never</strong> be used without antibiotic coverage, as this may result in significant worsening (including blinding) and may reduce recurrence-free survival time [<a href="#rid32">32</a>]. Intravitreal glucocorticoids maintain immunosuppressive concentrations over at least six to eight weeks [<a href="#rid43">43,44</a>] and thus require an extended period of at least six to eight weeks of antiparasitic therapy in order to prevent retinal necrosis as a consequence of uncontrolled parasite proliferation [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H3624947457"><span class="h2">Follow-up</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ophthalmologic exams</strong> – Patients require regular ophthalmologic examinations to monitor the response to therapy and to determine the duration of treatment. (See <a class="local">'Duration of treatment'</a> below.)</p><p></p><p class="bulletIndent1">The frequency of follow-up depends upon the proximity of the lesion to the central vision and the severity of vitreal infiltration. As an example, patients with central lesions are usually seen at least once weekly. </p><p></p><p class="bulletIndent1">Untreated patients should be seen four and eight weeks after the diagnosis (unless symptoms worsen), since lesion scarring should be complete by then. </p><p></p><p class="bulletIndent1">For most patients, regular visits are generally not necessary once a lesion has healed, since the risk of and time to recurrences are not predictable. However, we see those with macular disease every three months during the first year and every six to twelve months in the second year. Children with congenital ocular toxoplasmosis (even those with inactive disease) should also be followed on a regular basis for a period of time. (See  <a class="medical medical_review" href="/d/html/15835.html" rel="external">"Congenital toxoplasmosis: Treatment, outcome, and prevention", section on 'Disease monitoring'</a>.)</p><p></p><p class="bulletIndent1">In cases that do not appear to be responding to treatment, the diagnosis should be confirmed (if not previously done) and other diagnoses should be excluded (see <a class="local">'Diagnosis'</a> above). If the diagnosis is confirmed, systemic therapy can be supplemented by intravitreal <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>. (See <a class="local">'Antimicrobial therapy for ocular disease'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring toxicity of therapy </strong>– Patients should be monitored closely for toxicity to TMP-SMX- and pyrimethamine-containing regimens. Complete blood count, kidney function, and liver function tests should be obtained at baseline. These tests should be repeated weekly for the first two weeks, and then every two weeks thereafter [<a href="#rid46">46</a>]. Among those with ocular disease who require more prolonged treatment (more than six weeks), these parameters are monitored every four weeks until cessation of therapy. </p><p></p><p class="bulletIndent1">Common side effects of <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> include rash, nausea, and bone marrow suppression. Higher doses of <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a>, up to 50 to 100 mg daily, can be administered to manage hematologic abnormalities [<a href="#rid47">47</a>]. Sulfa-containing agents can lead to rash, fever, leukopenia, hepatitis, nausea, vomiting, diarrhea, crystalluria, and, rarely, more severe reactions such as Stevens-Johnson syndrome. Additional information can be found in the individual drug information topics within UpToDate.</p><p></p><p class="headingAnchor" id="H3674362270"><span class="h2">Duration of treatment</span><span class="headingEndMark"> — </span>Patients with ocular disease are usually treated for six weeks. Ocular findings that support treatment discontinuation include resolution of inflammation and retinitis. Lesion activity and cessation of vasculitis on <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">fluorescein</a> angiography are also useful to help determine if treatment can be stopped. </p><p>The ultimate duration also depends upon the specific regimen. Certain agents (eg, <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> monotherapy) require a longer course of treatment than others. In addition, in some settings, antimicrobial therapy may need to be extended if glucocorticoids are used. (See <a class="local">'Treatment regimens'</a> above and <a class="local">'Adjunctive glucocorticoids'</a> above.)</p><p>Some patients may benefit from a prophylactic regimen for a period of time after they complete their initial treatment course to prevent reactivation. This includes patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Infection with a virulent parasite strain (eg, those from South America) (see <a class="local">'Importance of genotypes'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of frequent recurrences within the last two years</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk of recurrence (immunocompromised patients, especially those with hematologic malignancies and advanced HIV infection)</p><p></p><p>Prophylactic therapy with TMP-SMX is administered as (160 mg TMP/800 mg SMX) every other day and is usually continued for a minimum of three months, depending on the medical situation and individual patient factors [<a href="#rid26">26,48</a>]. Prophylactic therapy with TMP-SMX has been found to reduce the risk of recurrent disease, but only as long as it is taken [<a href="#rid48">48,49</a>]; however, long-term prophylaxis is rarely given. </p><p class="headingAnchor" id="H2321063618"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113063.html" rel="external">"Society guideline links: Toxoplasmosis"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Toxoplasmosis, an infection with a worldwide distribution, is caused by the intracellular protozoan parasite, <em>Toxoplasma gondii</em>. Immunocompetent persons with primary infection are usually asymptomatic. However, in some individuals, <em>T. gondii</em> infection presents as ocular disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ocular infection can be asymptomatic and have evidence of inactive disease (eg, scarring) found on routine exam, or they can have signs and symptoms of active disease, typically posterior uveitis. Posterior uveitis can develop in the setting of recently acquired infection or reactivated disease. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with acute toxoplasmosis, the risk of developing symptomatic disease is related in part to which genotype is causing infection. As an example, in Europe and the United States, where genotype II is prevalent, 80 to 90 percent of individuals who become infected are asymptomatic. This is in contrast to South and Central America, where genotype I and atypical strains predominate and there are higher rates of symptomatic ocular disease. (See <a class="local">'Importance of genotypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Posterior uveitis due to ocular toxoplasmosis should be suspected in a patient who presents with visual loss or vitreal floaters along with an inflammatory retinal or chorioretinal lesion. The diagnosis of active ocular disease is typically suggested by findings on ophthalmologic examination (eg, marked vitreous inflammation accompanied by whitish retinal lesions representing retinochoroiditis) and supported by serologic testing and/or aqueous humor analysis. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with inactive ocular toxoplasmosis, even if newly detected, do not require treatment. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with active ocular toxoplasmosis, we suggest antimicrobial therapy (with or without glucocorticoids) in those with ocular findings or conditions that put them at risk for developing site-threatening disease, as described above (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). Although most cases of active ocular toxoplasmosis resolve spontaneously over the course of four to eight weeks, antimicrobial therapy may be associated with a reduction of the lesion size in active retinochoroiditis and faster visual recovery, as well as a reduction in the risk of recurrent infection. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For nonpregnant adults who require treatment, we prefer <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) rather than other regimens. Treatment with <a class="drug drug_general" data-topicid="9841" href="/d/drug information/9841.html" rel="external">pyrimethamine</a> plus <a class="drug drug_general" data-topicid="9960" href="/d/drug information/9960.html" rel="external">sulfadiazine</a> plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> is also reasonable and has traditionally been considered the treatment of choice for ocular toxoplasmosis. However, experts are increasingly using TMP-SMX, since limited evidence suggests these regimens have comparable efficacy and there appear to be fewer side effects with TMP-SMX. Alternative regimens (eg, for patients with a sulfonamide allergy) include <a class="drug drug_general" data-topicid="8957" href="/d/drug information/8957.html" rel="external">atovaquone</a> or <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, ideally in combination with pyrimethamine and leucovorin, as well as intravitreal <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>. (See <a class="local">'Treatment regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with significant vitreous inflammation and retinal vasculitis, we suggest adjunctive glucocorticoids two to three days <strong>after</strong> antimicrobial therapy has been started (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The rationale for using glucocorticoids is to help preserve vision. (See <a class="local">'Adjunctive glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Special considerations regarding treatment of pregnant women and children are discussed separately. (See  <a class="medical medical_review" href="/d/html/6756.html" rel="external">"Toxoplasmosis and pregnancy"</a> and  <a class="medical medical_review" href="/d/html/15835.html" rel="external">"Congenital toxoplasmosis: Treatment, outcome, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial treatment should be continued for a minimum of six weeks. The ultimate duration depends upon the choice of agent and the response to therapy. (See <a class="local">'Follow-up'</a> above and <a class="local">'Duration of treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H3308650720"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The authors and editors would like to recognize Michael Tolentino, MD, who contributed to previous versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dardé ML. Toxoplasma gondii, "new" genotypes and virulence. Parasite 2008; 15:366.</a></li><li><a class="nounderline abstract_t">Arantes TE, Silveira C, Holland GN, et al. Ocular Involvement Following Postnatally Acquired Toxoplasma gondii Infection in Southern Brazil: A 28-Year Experience. Am J Ophthalmol 2015; 159:1002.</a></li><li><a class="nounderline abstract_t">Ferreira AI, De Mattos CC, Frederico FB, et al. Risk factors for ocular toxoplasmosis in Brazil. Epidemiol Infect 2014; 142:142.</a></li><li><a class="nounderline abstract_t">Dubey JP, Lago EG, Gennari SM, et al. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology 2012; 139:1375.</a></li><li><a class="nounderline abstract_t">Vasconcelos-Santos DV, Machado Azevedo DO, Campos WR, et al. Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology 2009; 116:2199.</a></li><li><a class="nounderline abstract_t">Aleixo AL, Benchimol EI, Neves Ede S, et al. [Frequency of lesions suggestive of ocular toxoplasmosis among a rural population in the State of Rio de Janeiro]. Rev Soc Bras Med Trop 2009; 42:165.</a></li><li><a class="nounderline abstract_t">Ferreira IM, Vidal JE, de Mattos Cde C, et al. Toxoplasma gondii isolates: multilocus RFLP-PCR genotyping from human patients in Sao Paulo State, Brazil identified distinct genotypes. Exp Parasitol 2011; 129:190.</a></li><li><a class="nounderline abstract_t">Silveira C, Muccioli C, Holland GN, et al. Ocular Involvement Following an Epidemic of Toxoplasma gondii Infection in Santa Isabel do Ivaí, Brazil. Am J Ophthalmol 2015; 159:1013.</a></li><li><a class="nounderline abstract_t">Lindsay DS, Dubey JP. Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis. Parasitology 2011; 138:1829.</a></li><li><a class="nounderline abstract_t">Glasner PD, Silveira C, Kruszon-Moran D, et al. An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol 1992; 114:136.</a></li><li><a class="nounderline abstract_t">Jones JL, Holland GN. Annual burden of ocular toxoplasmosis in the US. Am J Trop Med Hyg 2010; 82:464.</a></li><li><a class="nounderline abstract_t">Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol 2003; 136:973.</a></li><li><a class="nounderline abstract_t">Kodjikian L, Wallon M, Fleury J, et al. Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol 2006; 244:14.</a></li><li><a class="nounderline abstract_t">Montoya JG, Remington JS. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis 1996; 23:277.</a></li><li><a class="nounderline abstract_t">Holland GN, Crespi CM, ten Dam-van Loon N, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. Am J Ophthalmol 2008; 145:1007.</a></li><li><a class="nounderline abstract_t">Rajput R, Denniston AK, Murray PI. False Negative Toxoplasma Serology in an Immunocompromised Patient with PCR Positive Ocular Toxoplasmosis. Ocul Immunol Inflamm 2018; 26:1200.</a></li><li><a class="nounderline abstract_t">Villard O, Filisetti D, Roch-Deries F, et al. Comparison of enzyme-linked immunosorbent assay, immunoblotting, and PCR for diagnosis of toxoplasmic chorioretinitis. J Clin Microbiol 2003; 41:3537.</a></li><li><a class="nounderline abstract_t">Garweg JG, de Groot-Mijnes JD, Montoya JG. Diagnostic approach to ocular toxoplasmosis. Ocul Immunol Inflamm 2011; 19:255.</a></li><li><a class="nounderline abstract_t">Greigert V, Di Foggia E, Filisetti D, et al. When biology supports clinical diagnosis: review of techniques to diagnose ocular toxoplasmosis. Br J Ophthalmol 2019; 103:1008.</a></li><li><a class="nounderline abstract_t">Greigert V, Pfaff AW, Sauer A, et al. Biological Diagnosis of Ocular Toxoplasmosis: a Nine-Year Retrospective Observational Study. mSphere 2019; 4.</a></li><li><a class="nounderline abstract_t">Rothova A, de Boer JH, Ten Dam-van Loon NH, et al. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology 2008; 115:306.</a></li><li><a class="nounderline abstract_t">Harrell M, Carvounis PE. Current treatment of toxoplasma retinochoroiditis: an evidence-based review. J Ophthalmol 2014; 2014:273506.</a></li><li><a class="nounderline abstract_t">Wakefield D, Cunningham ET Jr, Pavesio C, et al. Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm 2011; 19:2.</a></li><li><a class="nounderline abstract_t">Garweg JG, Stanford MR. Therapy for ocular toxoplasmosis--the future. Ocul Immunol Inflamm 2013; 21:300.</a></li><li class="breakAll">American Academy of Ophthalmology. https://www.aao.org/bcscsnippetdetail.aspx?id=bdb89d18-1a35-4cf7-bc91-b7031311462a (Accessed on November 27, 2019).</li><li><a class="nounderline abstract_t">Silveira C, Muccioli C, Nussenblatt R, Belfort R Jr. The Effect of Long-term Intermittent Trimethoprim/Sulfamethoxazole Treatment on Recurrences of Toxoplasmic Retinochoroiditis: 10 Years of Follow-up. Ocul Immunol Inflamm 2015; 23:246.</a></li><li><a class="nounderline abstract_t">Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol 1993; 115:517.</a></li><li><a class="nounderline abstract_t">Opremcak EM, Scales DK, Sharpe MR. Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis. Ophthalmology 1992; 99:920.</a></li><li><a class="nounderline abstract_t">Pradhan E, Bhandari S, Gilbert RE, Stanford M. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev 2016; :CD002218.</a></li><li><a class="nounderline abstract_t">de-la-Torre A, Stanford M, Curi A, et al. Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm 2011; 19:314.</a></li><li><a class="nounderline abstract_t">Kim SJ, Scott IU, Brown GC, et al. Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology. Ophthalmology 2013; 120:371.</a></li><li><a class="nounderline abstract_t">Reich M, Becker MD, Mackensen F. Influence of drug therapy on the risk of recurrence of ocular toxoplasmosis. Br J Ophthalmol 2016; 100:195.</a></li><li><a class="nounderline abstract_t">Reich M, Ruppenstein M, Becker MD, Mackensen F. Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosis. Retina 2015; 35:809.</a></li><li><a class="nounderline abstract_t">Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005; 112:1876.</a></li><li><a class="nounderline abstract_t">Zhang Y, Lin X, Lu F. Current treatment of ocular toxoplasmosis in immunocompetent patients: a network meta-analysis. Acta Trop 2018; 185:52.</a></li><li><a class="nounderline abstract_t">Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology 1999; 106:148.</a></li><li><a class="nounderline abstract_t">Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit 2012; 18:CR296.</a></li><li><a class="nounderline abstract_t">Martínez Castillo S, Gallego-Pinazo R, Francés-Muñoz E, et al. [Macular toxoplasmosis and intravitreal clindamycin: an alternative to oral treatment]. Arch Soc Esp Oftalmol 2012; 87:93.</a></li><li><a class="nounderline abstract_t">Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011; 118:134.</a></li><li><a class="nounderline abstract_t">Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol 2013; 33:39.</a></li><li><a class="nounderline abstract_t">Jasper S, Vedula SS, John SS, et al. Corticosteroids as adjuvant therapy for ocular toxoplasmosis. Cochrane Database Syst Rev 2017; 1:CD007417.</a></li><li><a class="nounderline abstract_t">Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol 2002; 134:34.</a></li><li><a class="nounderline abstract_t">Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol 2011; 22:517.</a></li><li><a class="nounderline abstract_t">Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006; 38:218.</a></li><li><a class="nounderline abstract_t">Nóbrega MJ, Rosa EL. Toxoplasmosis retinochoroiditis after photodynamic therapy and intravitreal triamcinolone for a supposed choroidal neovascularization: a case report. Arq Bras Oftalmol 2007; 70:157.</a></li><li><a class="nounderline abstract_t">Ben-Harari RR, Goodwin E, Casoy J. Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review. Drugs R D 2017; 17:523.</a></li><li class="breakAll">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguideline s/adult_oi.pdf (Accessed on March 04, 2016).</li><li><a class="nounderline abstract_t">Felix JP, Lira RP, Zacchia RS, et al. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol 2014; 157:762.</a></li><li><a class="nounderline abstract_t">Fernandes Felix JP, Cavalcanti Lira RP, Cosimo AB, et al. Trimethoprim-Sulfamethoxazole Versus Placebo in Reducing the Risk of Toxoplasmic Retinochoroiditis Recurrences: A Three-Year Follow-up. Am J Ophthalmol 2016; 170:176.</a></li></ol></div><div id="topicVersionRevision">Topic 5699 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814708" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Toxoplasma gondii, "new" genotypes and virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25743338" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ocular Involvement Following Postnatally Acquired Toxoplasma gondii Infection in Southern Brazil: A 28-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23507508" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk factors for ocular toxoplasmosis in Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22776427" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19744724" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448935" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : [Frequency of lesions suggestive of ocular toxoplasmosis among a rural population in the State of Rio de Janeiro].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21741380" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Toxoplasma gondii isolates: multilocus RFLP-PCR genotyping from human patients in Sao Paulo State, Brazil identified distinct genotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25743340" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ocular Involvement Following an Epidemic of Toxoplasma gondii Infection in Santa Isabel do Ivaí, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21902872" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Toxoplasma gondii: the changing paradigm of congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1642287" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An unusually high prevalence of ocular toxoplasmosis in southern Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20207874" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Annual burden of ocular toxoplasmosis in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14644206" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15906073" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ocular manifestations in congenital toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8842263" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18343351" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28700250" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : False Negative Toxoplasma Serology in an Immunocompromised Patient with PCR Positive Ocular Toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904352" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of enzyme-linked immunosorbent assay, immunoblotting, and PCR for diagnosis of toxoplasmic chorioretinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21770803" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnostic approach to ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31088793" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : When biology supports clinical diagnosis: review of techniques to diagnose ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31554726" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Biological Diagnosis of Ocular Toxoplasmosis: a Nine-Year Retrospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17669497" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25197557" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Current treatment of toxoplasma retinochoroiditis: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21250922" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Controversies in ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23617277" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Therapy for ocular toxoplasmosis--the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23617277" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Therapy for ocular toxoplasmosis--the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25325434" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The Effect of Long-term Intermittent Trimethoprim/Sulfamethoxazole Treatment on Recurrences of Toxoplasmic Retinochoroiditis: 10 Years of Follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8470726" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Therapy for ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1630782" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Trimethoprim-sulfamethoxazole therapy for ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27198629" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antibiotics versus no treatment for toxoplasma retinochoroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21970662" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Therapy for ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23062648" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26163541" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Influence of drug therapy on the risk of recurrence of ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25299969" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Time patterns of recurrences and factors predisposing for a higher risk of recurrence of ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16171866" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29704469" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Current treatment of ocular toxoplasmosis in immunocompetent patients: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9917796" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22534709" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22423660" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : [Macular toxoplasmosis and intravitreal clindamycin: an alternative to oral treatment].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20708269" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23053769" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28125765" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Corticosteroids as adjuvant therapy for ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12095805" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21897242" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Review and update of intraocular therapy in noninfectious uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763379" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Intravitreal triamcinolone acetonide: a change in a paradigm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505739" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Toxoplasmosis retinochoroiditis after photodynamic therapy and intravitreal triamcinolone for a supposed choroidal neovascularization: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28879584" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28879584" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24388839" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: randomized controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521607" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Trimethoprim-Sulfamethoxazole Versus Placebo in Reducing the Risk of Toxoplasmic Retinochoroiditis Recurrences: A Three-Year Follow-up.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
